Epidemiology, pathogenesis and treatment of irritable bowel syndrome

Author： Nam Jong H   Alnoah Zaid   Yenumula Sudha R   Murthy Sreekant  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.13, Iss.8, 2003-08, pp. : 1213-1267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rifaximin for the treatment of irritable bowel syndrome

By Cremonini Filippo   Lembo Anthony  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 433-440

Informa Healthcare

Access to resources Recommend Favorite

Asimadoline in the treatment of irritable bowel syndrome

By Mangel Allen W   Williams Valerie SL  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1257-1264

Informa Healthcare

Access to resources Recommend Favorite

Treatment Options for Irritable Bowel Syndrome Set to Increase

By  

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 1, 2004-05 ,pp. : 12-17

Adis International

Access to resources Recommend Favorite

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal   Berrada Driss   Lembo Anthony  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Probiotic Agents in the Treatment of Irritable Bowel Syndrome

By Guslandi M  

The Journal of International Medical Research, Vol. 35, Iss. 5, 2007-09 ,pp. : 583-589

Field House Publishing

Access to resources Recommend Favorite